Siemens Healthineers stock weighs strong 2026 finish against softer outlook

Siemens Healthineers finished fiscal 2026 with stronger momentum in its core businesses, but management is planning for slower earnings progress in the new year. In a press release published on November 5, the medical technology group reported results for the year ended September 30 and presented its fiscal 2027 targets.

A strong finish across core businesses

Comparable revenue increased 4.0 percent in fiscal 2026. Siemens Healthineers reported an adjusted EBIT margin of 16.2 percent, adjusted EBIT of around 3.8 billion euros and adjusted basic earnings per share of 2.42 euros. Free cash flow reached around 2.4 billion euros, while the company proposed an unchanged dividend of 1.00 euro per share.

The fourth quarter provided the strongest operational signal. Comparable revenue growth reached 5.9 percent, and the equipment book-to-bill ratio was 1.15. Imaging grew 10.0 percent on a comparable basis and posted an adjusted EBIT margin of 21.9 percent. Precision Therapy added 4.8 percent, with a 13.8 percent margin.

Diagnostics was the clear weak spot. Comparable revenue declined 4.2 percent in the quarter, and its adjusted EBIT margin was 5.4 percent. The contrast between the businesses matters for investors because growth in Imaging and Precision Therapy is currently carrying the group while Diagnostics works through pricing and market pressures.

Management sets a more cautious path

For fiscal 2027, Siemens Healthineers expects comparable revenue growth of 4.0 to 5.0 percent over the 2026 base. Adjusted basic earnings per share are forecast at 2.20 to 2.40 euros, below the 2.42 euros achieved in fiscal 2026.

Chief Executive Bernd Montag said the company is strengthening its core activities, positioning Diagnostics for the future and starting the carve-out process for that business. The strategy also includes a sharper focus on healthcare innovation and the company's portfolio of imaging, cancer care, minimally invasive therapies and in-vitro diagnostics.

The guidance leaves limited room for acceleration in the near term. Siemens Healthineers must convert healthy equipment demand into profitable growth while managing pressure in Diagnostics and executing portfolio changes. The unchanged proposed dividend provides continuity, but the earnings range places greater weight on delivery in the operating businesses.

Shares trade above the prior close

Siemens Healthineers stock traded at 43.74 euros on Lang & Schwarz at 11:39 CET on Thursday, November 12, 0.51 percent above the Xetra close of Wednesday, November 11. The move offers a modest market indication as investors assess the strong fourth-quarter performance against the lower 2027 earnings range.

Broader market sentiment remains relevant for large German healthcare and industrial names, with the DAX market environment providing the wider setting for the shares.

More news and analyses on Siemens Healthineers stock